RIGEMINAL neuralgia is a paroxysmal lancinating pain confined to a distribution encompassing one or more of the branches of the trigeminal nerve on one side of the face. It frequently arises in conjunction with a vascular contact between an artery or a vein and the trigeminal nerve at the REZ. This fact led to the hypothesis of a causal relationship between vessel compression and TN and the devising of MVD surgery. 2, 9, 10, 16 First-line treatment in patients with TN is medical therapy. Nonetheless, many patients with this condition eventually do not respond to medical therapy because of refractory pain or intolerable medication side effects. More invasive treatment options include MVD and neuronal modulating procedures such as glycerol rhizolysis, radiofrequency rhizotomy, percutaneous balloon microcompression, and peripheral nerve blocks. 2, 8, 9, 35, 36 In 1953 radiosurgery with x-rays was first used to treat TN, and the long-term success (Ͼ 17 years) of two patients following the procedure was first reported in 1971. 21 Since then, radiosurgery has been used to treat TN and has been viewed as a minimally invasive treatment option with few side effects. In various series, pain-free outcomes have ranged from 21.8 to 75%, and complication rates from 2.7 to 37%. 3, 4, 17, 18, 20, 28, 30, 31, 37, 38 Nevertheless, questions remain about the efficacy, safety, and durability of GKS for TN. In an effort to answer some of these questions, we report on our experience with GKS for the treatment of 136 patients with TN and atypical facial pain and we analyze the factors associated with a pain-free outcome. Object. Microvascular decompression (MVD) and percutaneous ablation surgery have historically been the treatments of choice for medically refractory trigeminal neuralgia (TN). Gamma knife surgery (GKS) has been used as an alternative, minimally invasive treatment in TN. In the present study, the authors evaluated the long-term results of GKS in the treatment of TN.
Clinical Material and Methods

Patient Population
At the University of Virginia, we retrospectively reviewed a prospectively created database to analyze patients treated with GKS for facial pain. From 1996 until 2004, 136 patients were treated; 122 had a diagnosis of TN, whereas 14 had a diagnosis of atypical facial pain (Table 1) . Ninetyfour patients had right-sided pain, whereas 42 patients had left-sided pain. The distribution of pain in the divisions of the trigeminal nerve in patients was as follows: V1 = 6.9%; V2 = 28.4%; V3 = 23.3%; V1 and V2 = 15.5%; V2 and V3 = 15.5%; and V1, V2, and V3 = 11.2%. Preoperative facial numbness was noted in 34 patients (25%).
The study population consisted of 66 men and 70 women, with a mean age of 68 years (range 22-90 years). The majority of the patients had at some point been treated with more than one pharmacological agent, and all patients were refractory to medical treatment. In addition, 74 patients had undergone previous surgical procedures for treatment of facial pain. Twenty-three patients (17%) underwent MVD, 46 (34%) injection of glycerol, two (2%) radiofrequency rhizotomy, and 32 (24%) neurectomy.
The median follow up was 19 months. The number of patients with 1-, 2-, and 3-year follow ups were 118, 64, and 39, respectively. Gamma knife surgery was considered a failure in patients who did not respond to treatment or who experienced early pain recurrence. Patients who had initially responded favorably but later experienced a recurrence of pain were considered for repeated radiosurgery.
Radiosurgical Technique
One hundred fifty-one GKSs were performed in 136 patients in this study; 14 underwent a second GKS and one patient underwent three surgeries. Radiosurgery was performed using the model U (1989 to June 2001) and model C (July 2001-present) gamma knives (Elekta Instruments, Norcross, GA). The Leksell model G headframe was applied to the patient in the main operating room once a local anesthetic agent together with light intravenous sedation (typically propofol or fentanyl and Versed) had been administered. Most patients were treated using one isocenter (median 1 isocenter, range one-seven isocenters), and radiation doses were delivered through the 4-mm collimator helmet.
Maximal radiation doses ranged from 50 to 90 Gy, and the median dose was 80 Gy. The maximal prescription doses were as follows: 50 Gy in 0.7% of the procedures, 60 Gy in 0.7%, 70 Gy in 43%, 80 Gy in 55%, and 90 Gy in 0.7%. In each case, the REZ was included within the treatment plan to allow a low dose of radiation (~ 20-30 Gy) to the edge of the pons. Doses less than 70 Gy were given only on repeated treatment. The chosen targeting center was typically 2 to 4 mm anterior to the junction of the trigeminal nerve and the pons. Targets were categorized into two groups: the first consisted of targets where the trigeminal nerve was covered with the 50% isodose outside of the brainstem (Fig.  1) . The second category of targets was where the 50% isodose curve was adjacent to the surface of the brainstem (Fig. 2) . Fifty-two percent of patients were treated using the first target strategy and 43% were treated using the second strategy. Five percent of patients had 4-mm isocenters used to cover the entire portion of the trigeminal nerve on the affected side. The senior author (L.S.) developed all GKS plans.
Imaging Techniques
The trigeminal nerve was typically imaged using a 1.5-tesla MR imaging unit (GE Medical Systems, Milwaukee, WI). Localization was performed using T 1 -weighted and fast-spin echo T 2 -weighted axial images along with coronal
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Gamma knife surgery for trigeminal neuralgia images of the nerve. The axial volume acquisition of 512 ϫ 216 matrices was divided into 1-mm sections without gaps. The T 1 -weighted images were also obtained after administration of Gd. Two patients underwent computerized tomography for targeting because of medical conditions (for example, a pacemaker) that prohibited MR imaging. Note, however, that computerized tomography is not ideal for targeting purposes.
435
Patient Follow Up
Clinical Follow Up. All patients were subject to direct clinical follow up every 3 to 6 months. If a clinical appointment was missed, a questionnaire was sent to the patient. On that questionnaire, patients were asked to assess their pain intensity, time to onset of pain relief, presence or absence of facial numbness, pharmacological agents taken for pain relief, and whether they had undergone additional surgical interventions for the treatment of facial pain. In addition, patients were specifically asked whether they were pain free or had experienced improvements in pain following GKS. They were also asked about the postoperative presence of new or worsened facial numbness.
Imaging Follow Up. All patients underwent routine MR imaging examinations 6 to 9 months after GKS. More specifically, T 1 -weighted sequences with and without a contrast agent and T 2 -weighted images were obtained to evaluate for any adverse consequences. If a patient experienced new facial numbness post-GKS, he or she underwent additional MR imaging studies at the time of the onset of the numbness to evaluate for any brain tissue changes.
Statistical Analysis
The descriptive statistics were computed using standard methods to calculate median or mean values. Univariate and multivariate analyses were performed to assess for variables predictive of a pain-free outcome after GKS. The following variables were assessed: right-sided pain; typical or atypical pain; patient age; sex; number of isocenters; target distance from nerve REZ (the 50% isodose curves either well outside of or adjacent to the brainstem); maximal radiation dose; imaging changes post-GKS; previous interventions (a previous MVD, glycerol injection, GKS, or neurectomy); increasing duration of time from diagnosis to GKS; distribution of pain; preoperative facial numbness; postoperative facial numbness; and recurrence of pain in patients who had undergone more than one GKS. The unpaired Student t-test or analysis of variance was used for continuous variables. Nominal or ordinal data were compared using the two-tailed Fisher exact test. All statistical analyses were conducted with the aid of commercially available software (Statview, version 5.01; SAS Institute, Cary, NC). Statistical significance was defined as a probability value less than or equal to 0.05.
Results
Clinical Outcome
The median follow up in the 136 patients was 19 months. The median interval from treatment to symptom improvement was 24 days (range 1-180 days). Few patients experienced a benefit more than 2 months following GKS. At the time of the last follow up, 44% of patients were pain free without medication and 56% still had some degree of pain ( Table 2 ). The percent of pain-free patients without medication at specific time points was as follows: at 1 year post-GKS, 47% (among 118 patients with 1 year of follow up); at 2 years, 45% (among 64 patients with 2 years of follow up); and at 3 years, 34% (among 39 patients with 3 years of follow up; Fig. 3 ). Similarly, those who experienced some improvement in pain post-GKS were as follows: at 1 year, 90% (of 118 patients with 1 year of follow up); at 2 years, 77 (of 64 patients with 2 years of follow up); and at 3 years, 70% (of 39 patients with 3 years of follow up; Fig. 4 ). Forty-six percent of the patients with typical TN (122 patients) were pain free at the last follow up, whereas only 29% of those with atypical TN (14 patients) were pain free (p = 0.35, t-test).
On follow up, 33 patients experienced a recurrence of pain following some initial relief. The median time to recurrence of facial pain was 12 months. Among those patients He underwent GKS at a maximal radiation dose of 70 Gy, and the target was set with the 50% isodose configuration line abutting the brainstem.
whose pain recurred, 14 underwent an additional GKS procedure, six had an MVD, four an injection of glycerol, and one a radiofrequency rhizotomy; five patients refused any further treatment.
Factors Statistically Associated With a Pain-Free Outcome
Following GKS, pain relief was monitored by serial physician assessments at approximately 3-month intervals. Most patients experienced pain relief within the first 2 months following GKS, although the relief did not always last.
To evaluate the efficacy of GKS in a rigorous fashion, we considered factors that were statistically related to a painfree outcome at the time of the last follow up. Seventeen factors in all were tested (Table 3) . On univariate analysis, right-sided pain (p = 0.0002) and a previous neurectomy (p = 0.04) were statistically related to a pain-free result. On multivariate analysis, right-sided pain (p = 0.032) and increasing age (p = 0.05) were related to a pain-free outcome. No other factor was significantly related (that is, p Ͼ 0.05) to a pain-free result following GKS.
Clinical Complications
Twelve patients (9%) experienced new numbness following GKS (Table 1 ). In our study, four (29%) of 14 patients who had undergone repeated GKS had new facial numbness. Eight (7%) of 122 patients who had undergone only one GKS procedure suffered new facial numbness. There was a statistically significant difference in the incidence of new facial numbness in these two groups (p = 0.002, t-test). We were unable to establish a significant relationship between radiation dose and postoperative facial numbness. No patient experienced the new onset of corneal reflex loss or anesthesia dolorosa.
Twenty-six patients had either new or worsened facial numbness following GKS. The severity of this numbness was as follows: 12 patients, mild numbness; 10, somewhat disturbing numbness; and four severe numbness. Twentyone (17%) of 122 patients who had undergone only one GKS suffered new or worsened facial numbness, whereas five (36%) of 14 patients who had undergone more than one GKS experienced new or worsened symptoms. This difference was not statistically significant (p = 0.14, t-test). In addition, 12 (26%) of 46 patients with a history of glycerol injection experienced new or worsened facial numbness compared with 14 (16%) of 90 patients without such history (p = 0.14, t-test). One patient among all of those treated reported the new onset of facial numbness post-GKS, a condition she believed was worse than the TN itself. This patient experienced numbness that led to excessive drooling, but she did not have anesthesia dolorosa.
Imaging Outcome
Imaging changes, including focal contrast enhancement or focal T 2 -weighted signal change (Fig. 5) , were demonstrated in nine patients (6.6%) post-GKS. Among these nine patients, four had no numbness, three had mild numbness, and two had severe numbness.
Discussion
Rationale for Using GKS to Treat TN
The underlying origin of TN has been the subject of intense investigation for more than a century. Research by Pfluger (1859) and Heidenhain 13 (1861) demonstrated that the proximal end of a nerve was more excitable than its distal end and that the excitability of the nerve increased near the region of a cross-section. tients underscores a true lack of understanding of the underlying pathophysiology of TN. 7 With the development of the gamma knife and a limited understanding of the neurophysiology of pain, Dr. Leksell was obsessively interested in the treatment of patients with intractable pain. 14, 17, 22, 34 In his book Brain Fragments, Dr. Leskell wrote, One can accept death, but one cannot accept the deep, devastating pain. Sharp, intractable pain is like hell 'without escape, without hope and without Heliotrope when Venom burns.' Standing at the bedside without ever having experienced pain, it is impossible to imagine the patient's agony, and it is impossible to understand that a short time without pain can be extreme happiness. 21 As soon as he developed a new technique, Leksell would try it in the management of both intractable pain and tic douloureux. 21, 22 With the gamma knife unit installed in Stockholm, he asked Dr. Hakanson to find the two patients treated with orthovoltage for TN. Following the successful long-term outcome of these two patients, Drs. Leksell and Hakanson treated 48 patients between 1970 and 1978, and follow-up information was available in 46 of these patients (S. Hakanson, personal communication, 2004) . 22 In the first 24 patients, plain stereotactic skull x-ray films were used for targeting, and 33% of the patients were pain free at 6 months whereas only 8.3% were pain free at a mean follow up of 26 months (S. Hakanson, personal communication, 2004). In the remaining 22 patients, the position of the gasserian ganglion was determined using transoval cisternography with tantalum dust. For this group, the percent of pain-free patients at 6 and 26 months were 59% and 18%, respectively (S. Hakanson, personal communication, 2004) .
After an initial flurry of activity by Drs. Leksell and Hakanson, however, the use of the gamma knife in treating TN nearly vanished until Rand and colleagues 29 began to use it and reported satisfactory results. This lull in activity was partially due to the difficulty in targeting, and this problem was surmounted with the advent of MR imaging. Another cause for the resurgence of interest in GKS was the change in the target from the gasserian ganglion to the REZ. Following the publication of the report by Rand and associates, some researchers asserted that radiosurgery would replace MVD. Those conducting major series have reported painfree results of 21.8 to 75% and pain improvement of 65 to 88% following GKS (Table 4) . Authors of most of these studies have noted that radiation dose, history of previous surgery, and radiographic evidence of vascular compression to the trigeminal nerve were statistically related to a more favorable outcome. Nonetheless, considering the complication rates of 2.7 to 37% in these series, only the results reported by Young, et al., 38 appear comparable to those from large MVD series.
Overall, the treatment of choice for TN remains MVD. Nonetheless, in patients who are ineligible or unwilling to undergo more invasive neurosurgical procedures, GKS offers a reasonable alternative. Furthermore, GKS also does not carry the same type and degree of risks as those for MVD. For instance, in a long-term series of patients who had undergone MVD, there were the following risks: death 0.2%; brainstem infarction 0.1%; and hearing loss 1%. 2 None of these complications was observed in our series and neither has any been associated with the radiosurgical treatment of TN at other major centers. Ultimately, the patient must choose the type of intervention he or she is willing to undergo.
Problems With Comparing Treatment Modalities for TN
Although most studies share the same end point of pain FIG. 5. A T 1 -weighted Gd-enhanced MR image obtained in a 71-year-old woman who had presented with right-sided TN, revealing enhancement of the nerve and adjacent brainstem. She underwent GKS targeted on the nerve (similar to the targeting depicted in Fig. 1 ). The patient became pain free but experienced mild facial numbness.
relief, the patient populations in microsurgical and radiosurgical studies are often quite different. Many patients referred for GKS are older, have undergone prior surgeries with little or no benefit, possess many pretreatment neurological deficits, and are not good surgical candidates for several reasons. 2, 18, 28 Patient population biases make it difficult to compare the different treatment modalities simply on the basis of a standard end point. As is true for so much of neurosurgery, a randomized study of surgical interventions for the treatment of TN would be helpful.
Along similar lines, it is even difficult to compare radiosurgical outcomes from multiple centers. Clearly, GKS for TN is one of the more straightforward types of radiosurgical cases. Most patients are treated using one isocenter, and the doses applied vary extremely little. Nevertheless, there is a wide range of pain-free and pain-relief outcomes. Some of the differences in outcomes among radiosurgical centers may be a result of the different patient populations. For instance, some centers may treat more patients experiencing TN for the first time who have not had previous surgical interventions. Other causes for the difference in reported outcomes presumably depend on the manner in which data were gathered (for example, neurosurgical evaluation, mailed questionnaire, or phone survey, referring physician interview, and so forth), length of follow up, and the rigorous criteria used to meet either pain-relief or pain-free status. In our study, the 44% pain-free outcome (without medication) at the last follow up and the 70% pain-relief outcome at 3 years post-GKS are within the range reported from other centers (Table 4) . For example, these results are in close agreement with those reported by Brisman, et al. 5 In that series of 179 patients, the authors reported an excellent outcome (no pain without medication) in 41% of patients.
We believe it is better to grade patient outcome in an intuitive and straightforward manner by reporting pain-free outcomes without medication. Such an end point is readily understandable to patients, neurosurgeons, and referring physicians of all backgrounds. Reporting outcomes in terms of subjective degrees of pain relief may lead to confusion for patients and physicians alike. To compare our results with those of other studies in which pain relief rather than pain-free outcomes was described, we did note the number of patients who reported improvements in TN. In our study, "pain relief" meant that although a patient was still on medication, he or she thought the pain was improved following GKS. This result is arguably very meaningful to patients with severe pain and can translate into a significant improvement in the quality of life.
The variable history of TN is the other major difficulty in analyzing results from small to medium sized retrospective studies. Trigeminal neuralgia can be characterized by spontaneous partial or complete remissions. Its characteristic waxing and waning as well as the subjectivity of pain, sensory loss, and paresthesias make a longer follow-up period and straightforward end points essential.
Prognostic Factors for Pain Relief
In our study, results of univariate analysis revealed that a right-sided pain distribution and a previous neurectomy were related to a pain-free outcome. Results of multivariate analysis revealed that right-sided pain and patient age correlated with a pain-free outcome. It is notable that a painfree outcome was not related to radiation dose, sensory loss, slight differences in target selection, or the type of pain (that is, either atypical or typical TN). Although it is difficult to explain why sidedness of trigeminal pain should affect outcome, this same relationship was observed in a large series of patients who underwent MVD. 36 The relationship between a previous neurectomy and GKS in terms of a painfree outcome indicates that the efficacy of GKS may not be reduced after a peripheral neurectomy. Clearly, the GKS and peripheral neurectomy target proximal and distal portions of the symptomatic trigeminal nerve, respectively. In a subset of patients, both the proximal and distal portions of the nerve may require lesioning to provide adequate pain relief. The effect of patient age on outcome may be due in part to the generally older age of a patient treated with GKS (median age 68 years) and to the fact that many of these patients had undergone GKS as a first-line treatment.
Different researchers have reported on other factors associated with a better response to GKS, including typical TN rather than atypical pain from multiple sclerosis or other causes, 5, 6 higher doses of radiation, 27 a target closer to the brainstem, 6 and no prior surgery. 6, 20 Another favorable prognostic factor in patients with no prior surgical intervention is MR imaging evidence of blood vessel contact with the trigeminal nerve. 5 In the present study, we observed no relationship between these factors and pain-free outcome.
Complications of GKS
The most frequent complication following GKS for TN is facial numbness. The incidence of new trigeminal dysfunction varies from 6 to 66%. 19, 20, 24, 26, 27 Pollock, et al., 27 reported an association between greater radiation doses and the risk of trigeminal nerve dysfunction. In that study, 54% of patients treated with 90 Gy radiation experienced facial numbness, whereas only 15% of patients treated with 70 Gy radiation had a similar problem. In our series, 12 (9%) of 136 patients experienced new facial numbness following GKS. In our study, only one patient received a 90-Gy dose and no facial numbness was noted in this case. Fortunately, we observed neither anesthesia dolorosa nor the absence of the corneal reflex in the 136 patients.
In our study, 29% of the patients who had undergone repeated GKS suffered new facial numbness, whereas 7% of the patients who had undergone only one GKS experienced new facial numbness (p = 0.002, t-test). In a series of 18 patients who had undergone repeated radiosurgery, Herman, et al. 15 noted an 11% incidence of new or worsened facial numbness-not substantially greater than the risk of facial numbness in those with only one GKS. In contrast, Hasegawa, et al. 12 and Shetter, et al., 32 noted an increased risk of facial numbness associated with repeated GKS. Intuitively, it seems that the risk of facial numbness following repeated GKS, even with dose reduction, would be greater than that following one surgery alone. Nonetheless, the true incidence of facial numbness following GKS is not yet known and will require more extensive studies.
Conclusions
Gamma knife surgery is a relatively safe and effective treatment option in patients with medically refractory TN. The minimally invasive nature of GKS makes this approach attractive for those patients with significant comorbidities or an aversion to the more invasive yet more efficacious approach of MVD. The improvements in pain following GKS diminish somewhat with time, but this is true with other treatments as well. The time interval between treatment and pain improvement as well as the durability of the result remains the major limiting factor for GKS of TN.
